
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the very company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
After having to pull its compounded semaglutide modeled after Novo Nordisk’s weight loss drugs, Wegovy and Ozempic, Hims & Hers announced in a press release that the two firms have entered into a strategic partnership, making Novo Nordisk’s obesity drugs available through the telehealth platform.